Member News

November 10, 2025

FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified therapeutics company, announced it is expanding its intellectual property portfolio with the recent filing of two additional patent applications with the United States Patent and Trademark Office.

The first application applies to Tivic’s TLR5 agonist portfolio, which includes Entolimod and Entolasta. The patent titled “Immunomodulatory Pathway Modifying Agents and Uses of Same for Cancer Therapy” relates to the potential newly identified applications of TLR5 agonists such as Entolimod and Entolasta, as an adjunctive therapy to improve the effectiveness of T-cell, NK-cell and other immuno-oncology cell-based therapies for advanced-stage cancer. Patients receiving such therapies are often immunocompromised from earlier treatment regimens, and TLR5 agonists, used as an adjunctive therapy, may enhance outcomes. The second application, “Vagus Nerve Electrical Stimulation System,” covers device parameters that have been shown to have optimal impact on autonomic system activity via non-invasive vagus nerve stimulation.

“As we expand and protect our intellectual property rights, we are creating new potential areas for partnerships that can expand the market opportunities for our product candidates,” stated Jennifer Ernst, CEO of Tivic. “While our commercial focus remains on the advancement of Entolimod toward a biologics license application for acute radiation syndrome, we would welcome opportunities to partner with other therapeutic companies whose products may benefit from enhanced immune activation.”

About Tivic Health Systems

Tivic’s dual platform utilizes the body’s biopharmaceutical and bioelectronic systems to treat unmet medical needs through targeting the immune system.

Tivic’s biologic compounds activate an innate immune pathway to prevent cell death in the bone marrow and epithelial tissues across systems impacted by radiation and age. The company’s lead drug candidate, Entolimod™, is a novel TLR5 agonist that has been granted Fast Track and Orphan Drug designations for acute radiation syndrome and is in late-stage development. The company also holds rights to develop Entolimod and its immunologically optimized derivative, Entolasta, for neutropenia.

Tivic’s bioelectronic program has been developing a novel, non-invasive medical device designed to target the neural pathways implicated in many prevalent and debilitating diseases. Early trials showed promising signals that Tivic’s approach may regulate specific biologic responses and downregulate an overactive immune system. The company believes its early-stage vagus nerve stimulation device has the potential to deliver clinical outcomes similar to or better than those of surgically implanted devices.